Highlights Ascentage Pharma Group International Nasdaq

Stocks

AAPG

US04390B1052

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:01:00 2026-06-11 pm EDT			5-day change	1st Jan Change
16.96 ^USD	-0.62%		-4.48%	-34.95%

Jun. 10	B. Riley Initiates Ascentage Pharma Group International at Buy With $45 Price Target	MT
May. 31	Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP At ASCO 2026	CI

Highlights

May. 31	Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP At ASCO 2026	CI
May. 31	Ascentage Pharma Group International Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026	CI
May. 31	Ascentage Pharma Group International Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026	CI
May. 13	Ascentage Pharma Group International Presents 17 Clinical Advances At European Hematology Association Congress	CI
Apr. 22	Ascentage Pharma Group International Presents Data from Multiple Trials at ASCO 2026	CI
Apr. 20	Ascentage Pharma Group International Presents Four Preclinical Studies Demonstrating Potential Of Combination Therapies At American Association For Cancer Research 2026 Annual Meeting	CI
Mar. 26	Ascentage Pharma's 2025 Loss Widens, Revenue Falls	MT
Mar. 25	Ascentage Pharma's 2025 Loss Widens	MT
Mar. 25	Ascentage Pharma Group International posts FY loss increased to RMB1,243 million	RE
Mar. 25	Ascentage Pharma Group International Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 22	Ascentage Pharma Includes Risento In Reimbursement List Of Commercial Health Insurance Policies In Multiple Regions	CI
Feb. 06	Ascentage Pharma Says Bruton's Tyrosine Kinase-Targeted Protein Degrader Application Gets China Clearance	MT
Feb. 05	Ascentage Pharma Group International Announces IND Clearance by the China CDE for BTK Degrader APG-3288	CI
Jan. 06	Ascentage Pharma Group International Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288	CI
Dec. 09	Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%	CI
Dec. 09	Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP	CI
Dec. 09	Ascentage Pharma Group International Presents Updated Data for Ascentage Pharma?S Olverembatinib in Second-Line Cml-Cp Showing Encouraging Potential for Early-Line Treatment	CI
Dec. 07	Ascentage Pharma Group International Presents Encouraging Data from Phase Ib/Ii Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Exposed Patients with Myeloid Malignances	CI
Dec. 06	Ascentage Pharma Group International Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology Annual Meeting	CI
Dec. 04	Ascentage Pharma Group International Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ All Cleared by US FDA and EMA	CI
Dec. 04	Ascentage Pharma Wins U.S., E.U. Clearance for Global Phase 3 Olverembatinib Study	MT
Dec. 04	Ascentage Pharma Group International says phase III study of olverembatinib cleared by FDA, EMA	RE
Nov. 25	Ascentage Pharma Group International Inc. Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data Inastrointestinal Stromal Tumors in Nature's Signal Transduction and Targeted Therapy	CI
Nov. 04	Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of Olverembatinib, Lisaftoclax, APG-5918	CI
25-10-07	Ascentage Pharma Group International to Participate in Three Upcoming Investor Conferences in October 2025	CI